Direct Biologics, LLC

Apollo Endosurgery, Inc was founded upon the initial work of Apollo Group, an international think tank of world-renowned gastroenterologists and surgeons from five leading universities ( Mayo Clinic, Johns Hopkins, Medical University of South Carolina, University of Texas Medical Branch-Galveston and Chinese University-Hong Kong. ) Disappointed with the pace of innovation in therapeutic flexible endoscopy, the Group assembled in 1998 ( Timeline ) with the goal to advance the new discipline ; their specific focus was the use of long, flexible instruments deployed through a natural orifice in order to diagnose and potentially treat gastrointestinal disorders.The Group conducted its first preclinical NOTES studies in 2001 and published its first NOTES literature in 2002. During that period, the Apollo Group's efforts resulted in 17 issued patents, 35 applications in review and 130 disclosures. In 2006, Apollo Endosurgery, Inc was founded to commercialize the Group's inventions and innovations in the areas of NOTES ( Translumenal Surgery ) and Therapeutic Endoscopy ( Intralumenal Surgery ). Additionally, Apollo, Inc is committed to the advancement of less invasive therapies through ongoing research and development, and external partnerships, as well as relationships with key clinicians and the leading medical societies.The Apollo Group Co-Founders and Innovation Partners include: Peter Cotton, Christopher Gostout, Robert Hawes, Sergey Kantsevoy, Anthony Kalloo, Pankaj Pasricha and Sydney Chung. This Group, along with the Apollo corporate team, is recognized globally as respected thought leaders in Therapeutic Endoscopy, clinical experts in trial testing design, innovators of new products and, as an engine for future commercial development of GI and minimally invasive products.Committed to the advancement of therapeutic flexible endoscopy and other, less invasive therapies through ongoing research and development and external partnerships, as well as relationships with key clinicians and the leading medical societies.

Genprex, Inc. is a clinical-stage gene therapy company based in West Lake Hills, Texas, dedicated to developing innovative therapies for patients suffering from cancer and diabetes. The company focuses on providing life-changing gene therapies to individuals with limited or no treatment options, aiming to improve patient outcomes through advanced medical advancements. With a commitment to pioneering gene therapies, Genprex employs novel approaches such as reintroducing tumor suppressor genes to combat cancer and stabilizing glucose levels in diabetes. The company has received multiple FDA Fast Track Designations and is actively engaged in clinical trials to bring hope to patients worldwide. Generated from the website

Celling Biosciences is a biotech company based in Austin, TX, specializing in the research and development of autologous cellular therapy. Their innovative technology allows users to regulate and select specific cell types through a patented collection window and integrated ultra-filtration system, making them the first company to offer such a system on the market. With a focus on optimizing consistent, reliable, and reproducible cell therapy solutions, Celling Biosciences is at the forefront of next-generation medicine. Offering a range of products including PRP kits, bone marrow aspiration devices, and bone marrow concentration kits, Celling Biosciences is dedicated to scientifically changing the field of medicine. Their devices and techniques are designed to recover a high percentage of cells and growth factors, providing physicians with precise control and customizable solutions to meet their clinical requirements. With a team of scientists and engineers committed to innovation, Celling Biosciences is revolutionizing autologous tissue processing and transforming the science of stem cells into practical medical solutions.Generated from the website